dabigatran has been researched along with Carcinoma, Hepatocellular in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aigner, E; Balcar, L; Bartl, S; Datz, C; Gensluckner, S; Hametner-Schreil, S; Hofer, H; Lampichler, K; Lindorfer, A; Mandorfer, M; Pomej, K; Reiberger, T; Schäfer, B; Scheiner, B; Schöfl, R; Semmler, G; Trauner, M; Zoller, H | 1 |
| Dibiasi, C; Gratz, J; Wiegele, M | 1 |
2 other study(ies) available for dabigatran and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Outcome of Budd-Chiari Syndrome Patients Treated With Direct Oral Anticoagulants: An Austrian Multicenter Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Austria; Budd-Chiari Syndrome; Carcinoma, Hepatocellular; Dabigatran; End Stage Liver Disease; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Retrospective Studies; Severity of Illness Index; Vitamin K | 2023 |
Orthotopic liver transplantation in a patient receiving apixaban for portal vein thrombosis.
Topics: Aged; Blood Loss, Surgical; Carcinoma, Hepatocellular; Dabigatran; Humans; Infusions, Intravenous; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Mesenteric Vascular Occlusion; Mesenteric Veins; Pyrazoles; Pyridones; Risk Assessment; Thromboembolism; Tranexamic Acid; Venous Thrombosis | 2019 |